Search for Articles:
Title / Keyword
Author / Affiliation / Email
Journal
Article Type
 
 
Advanced Search
 
Section
Special Issue
Volume
Issue
Number
Page
 
3.6
3.6
Journals
Diagnostics
Special Issues
State of the Art of Bladder Cancer: From Diagnosis to...
share announcement

State of the Art of Bladder Cancer: From Diagnosis to Therapy

A special issue of Diagnostics (ISSN 2075-4418). This special issue belongs to the section "Pathology and Molecular Diagnostics".

Deadline for manuscript submissions: closed (31 October 2022) | Viewed by 3240

Special Issue Editor

Dr. Mauro Giuseppe Mastropasqua

E-Mail Website
Guest Editor
Department of Emergency and Organs Transplantation, Section of Pathology, School of Medicine, University of Bari “Aldo Moro”, Piazza Giulio Cesare 11, 70124 Bari, Italy
Interests: breast cancer; prognostic and predictive factors; sentinel node; DCIS; prostate cancer; urinary bladder cancer; kidney cancer; molecular pathology; pathology
Special Issues, Collections and Topics in MDPI journals

Special Issue Information

Dear Colleagues, 

Urinary bladder cancer is a common disease, mostly found in advanced age people. Age is not the only risk factor, of course—many other causes are related to the development of bladder cancer: gender and ethnicity, smoking, alcohol intake, chemical carcinogens, analgesics, chemotherapy and radiotherapy, chronic cystitis, and schistosomiasis. A diagnosis is made with the clinical evaluation of symptomatology and instrumental analyses, more simple strategies being, e.g., urinalysis to search blood in urine or urine cytology to search neoplastic cells, and more complex examples being, e.g., cystoscopy or CT scan or MRI.

Nevertheless, histology plays the main role in the diagnosis, useful not only to confirm the malignancy, but also to assess invasiveness and the depth of invasion, if any. In addition to quantification of the disease, histology can also provide information about quality through the evaluation of grade of differentiation and the identification of a special type of bladder cancer.

Recent molecular studies, such as for other solid tumors (i.e., breast cancer), have further detailed the quality of this disease through biomarkers that demonstrate that there are two types of urinary bladder cancer, indicated as luminal and basal types with distinct clinical outcomes and different sensitivities to therapies.

Considering this, we would like to give readers an all-inclusive knowledge of all innovations in the diagnosis and treatment of bladder cancer to properly enhance patient care.

This Special Issue is aimed at gathering contributions and novelties with regard to all features covering this topic, starting from both clinico-instrumental and pathological diagnosis, to therapy, encompassing both established and new treatment modalities, including recent immunotherapy.

Prof. Dr. Mauro Giuseppe Mastropasqua
Guest Editor

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Diagnostics is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.

Keywords

  • urinary bladder cancer
  • biomarkers
  • histology
  • grading and staging
  • molecular subtyping
  • prognosis
  • precision medicine

Published Papers (2 papers)

Download All Papers
Order results
Result details
Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:

Research

Jump to: Other

11 pages, 403 KiB  
Article
Robot-Assisted Radical Cystectomy: A Single-Center Experience and a Narrative Review of Recent Evidence
by Bernardo Rocco, Giulia Garelli, Simone Assumma, Filippo Turri, Mattia Sangalli, Tommaso Calcagnile, Giorgia Gaia, Stefano Terzoni, Guglielmo Oliviero, Daniele Stroppa, Enrico Panio, Luca Sarchi, Alberto del Nero, Giorgio Bozzini, Angelica Grasso, Paolo Dell’Orto and Maria Chiara Sighinolfi
Diagnostics 2023, 13(4), 714; https://doi.org/10.3390/diagnostics13040714 - 14 Feb 2023
Cited by 1 | Viewed by 1332
Abstract
Radical cystectomy represents one of the most challenging surgical procedures, exhibiting a high morbidity rate. The transition to minimally invasive surgery in the field has been steep, due to either the technical complexity and prior concerns of atypical recurrences and/or peritoneal spread. More [...] Read more.
Radical cystectomy represents one of the most challenging surgical procedures, exhibiting a high morbidity rate. The transition to minimally invasive surgery in the field has been steep, due to either the technical complexity and prior concerns of atypical recurrences and/or peritoneal spread. More recently, a larger series of RCTs has proven the oncological safety of robot-assisted radical cystectomy (RARC). Beyond survival outcomes, the comparison between RARC and open surgery in terms of peri-operative morbidity is still ongoing. We present a single-center experience of RARC with intracorporeal urinary diversion. Overall, 50% of patients had an intracorporeal neobladder reconstruction. The series confirms a low rate of complications (Clavien Dindo ≥ IIIa 7.5%) and wound infections (2.5%) and the absence of thromboembolic events. No atypical recurrences were found. To discuss these outcomes, we reviewed the literature related to RARC including level-1 evidence. PubMed and Web of Science searches were performed using the medical subject terms “robotic radical cystectomy” and “randomized controlled trial (RCT)”. Six unique RCTs comparing robot and open surgery were found. Two clinical trials dealt with RARC with an intracorporeal reconstruction of UD. Pertinent clinical outcomes are summarized and discussed. In conclusion, RARC is a complex but feasible procedure. The transition from extracorporeal urinary diversion (UD) to a complete intracorporeal reconstruction could be the key to improving peri-operative outcomes and reducing the whole morbidity of the procedure. Full article
(This article belongs to the Special Issue State of the Art of Bladder Cancer: From Diagnosis to Therapy)
►▼ Show Figures

Figure 1

Other

Jump to: Research

13 pages, 2665 KiB  
Systematic Review
The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis
by Weitao Zheng, Tianhai Lin, Zeyu Chen, Dehong Cao, Yige Bao, Peng Zhang, Lu Yang and Qiang Wei
Diagnostics 2022, 12(8), 2005; https://doi.org/10.3390/diagnostics12082005 - 19 Aug 2022
Viewed by 1347
Abstract
Background: Fluorescence in situ hybridization (FISH) has become a popular biomarker for subsequent monitoring the recurrence of non-muscle invasive bladder cancer (NMIBC), several studies have investigated the ability of FISH to detect recurrence in the surveillance of NMIBC. However, the results were inconsistent. [...] Read more.
Background: Fluorescence in situ hybridization (FISH) has become a popular biomarker for subsequent monitoring the recurrence of non-muscle invasive bladder cancer (NMIBC), several studies have investigated the ability of FISH to detect recurrence in the surveillance of NMIBC. However, the results were inconsistent. Methods: We conducted a systematic literature search extensively on authenticated databases including PubMed/Medline, Embase, Web of Science, Ovid, and Cochrane Library. Meta-analysis was performed to find out the sensitivity and specificity of FISH in predicting recurrence of NMIBC. Results: 15 studies were ultimately included in this meta-analysis, a total of 2941 FISH evaluations from 2385 NMIBC patients were available. The pooled sensitivity of FISH was 68% (95% CI: 0.58–0.76), and the pooled specificity was 64% (95% CI: 0.53–0.74). Subgroup analyses were performed in 7 studies without Bacillus Calmette–Guerin (BCG) treatment, the pooled sensitivity was 82% (95% CI: 0.68–0.90), and the pooled specificity was 63% (95% CI: 0.37–0.82). And in 9 studies using “UroVysion standard” to define positive FISH results showed a pooled sensitivity of 60% (95% CI: 0.50–0.70) and specificity of 70% (95% CI: 0.61–0.78). Conclusions: The findings of this study indicate that FISH has a satisfactory sensitivity (68%) and specificity (64%) and could be a potential biomarker in the surveillance of NMIBC. Moreover, BCG treatment and different FISH methods may have an impact on the sensitivity and specificity, these factors should be taken into account when making clinical strategy. Full article
(This article belongs to the Special Issue State of the Art of Bladder Cancer: From Diagnosis to Therapy)
►▼ Show Figures

Figure 1

Show export options expand_more Show export options expand_less
Select all
Export citation of selected articles as:
 
Displaying articles 1-2
Back to TopTop